SITEMAP

• Science
  • Cutting Edge Science
  • Inspiration and Innovation
  • Acquired Thrombotic Thrombocytopenic Purpura (ATTP)
    • Cutting Edge Science
      • 2022
        • Rapidly identifying thrombotic thrombocytopenic purpura (TTP) can save lives¹
        • Rapidly identifying thrombotic thrombocytopenic purpura (TTP) can save lives¹
        • Rapidly identifying thrombotic thrombocytopenic purpura (TTP) can save lives¹
        • Tools to support a clinical aTTP diagnosis
        • Rapidly identifying thrombotic thrombocytopenic purpura (TTP) can save lives¹
        • ISTH Guidelines
      • 2023
        • ISTH Guidelines for the Diagnosis and Management of aTTP (iTTPa)
        • Plasmic Score
        • aTTP is a Medical Emergency With Long Term Consequences
      • 2024
  • Anti-Infectives
    • Cutting Edge Science
      • 2023
  • Asthma
  • Atopic Dermatitis
    • Cutting Edge Science
      • 2021
        • About Type 2 Inflammation – Atopic Dermatitis
      • 2024
        • Atopic Dermatitis Pathophysiology: Breaking Down the Barrier
      • Innovation
        • Atopic Dermatitis story
        • Patient Case – Dupilumab in Atopic Dermatitis
  • Cardiovascular
    • Atherothrombosis
      • Cutting Edge Science
        • Innovation
          • 2022
            • Single Antiplatelet therapy: Insights on earlier use
            • Clopidogrel as the standard of care for elective PCI: Findings from the Alpheus
            • Understanding de-escalation in Antiplatelet therapy
            • Management of antithrombotic therapy in patients with AF undergoing PCI
          • 2023
            • No Rebound Effect Post Clopidogrel Withdrawal
            • Insights and impacts from the TALOS-AMI Trial
            • DAPT in Elderly with CAD Meta Analysis
            • Effectiveness and safety of Clopidogrel vs Aspirin
        • 2022
          • Ticagrelor vs Clopidogrel in ACS patients undergoing PCI in routine clinical practice
          • In hospital outcomes in young patients with AMI: Results from Gulf Coast
          • Adherence and persistence analysis in patients treated with DAPT
          • Effect of de-escalated P2Y12 inhibitor switching in dual antiplatelet therapy (DAPT)
          • Is Clopidogrel a viable first choice P2Y12 inhibitor for DAPT after PCI?
        • 2023
          • De-escalation to Clopidogrel in AMI
          • Ticagrelor vs Clopidogrel in high bleeding risk patients with ACS
          • P2Y12 inhibitors after Coronary stenting
          • Smart-choice trial_P2Y12 inhibitor monotherapy in complex PCI
          • The SWITCH study: antiplatelet-switching strategy after coronary interventions
          • ESC 2021 - Antiplatelet therapy in high bleeding risk patients with or without OAC therapy
          • ESC 2021 - Dual Antiplatelet Therapy After Coronary Stenting in High Bleeding Risk Patients
          • DAPT for secondary prevention of AIS
          • Clopidogrel Based Strategies in ACS
          • Net clinical benefit of Clopidogrel vs Ticagrelor
          • New Users of Ticagrelor / Clopidogrel Observational Study in Sweden
          • Clopidogrel vs Ticagrelor in ACS
          • Ticagrelor vs Clopidogrel in high bleeding risk patients with ACS
          • De-escalation of DAPT for ACS
          • Unguided de-escalation from Ticagrelor to Clopidogrel
          • Potent P2Y12 Inhibitors vs Clopidogrel in elderly ACS patients
          • DAPT de-escalation vs standard DAPT
          • Clopidogrel monotherapy after very short DAPT
          • P2Y12 inhibitor adherence trajectories in ACS
          • Clinical outcome of switching from Clopidogrel to Ticagrelor
    • Dyslipidemia
      • Cutting Edge Science
        • 2021
          • Long-term effectiveness and safety of statin therapy
          • Switching From Statin Monotherapy to Statin/Ezetimibe Combination
          • Heart UK Reviews Safety of Lipid Lowering Medications in Patients with COVID-19
          • The ACTE Study
          • The ROSETTE Study
          • The Explorer Study
          • Regulate LDL-C level for those undergoing coronary revascularization (Diabetic Patients)
          • Optimal use of LLT after ACS
          • ESC/EAS 2019 Guidelines for the management of dyslipidaemias
          • Key Learnings in Dyslipidemia by Prof. Kausik Ray - 2021 EAS Congress
        • Innovation
          • 2022
            • Lp(a) as ASCVD risk factor
            • Dyslipidemia performance of 2016 2019 and 2021 ESC Dyslipidemia guidelines
            • The role of the patient in Achieving LDL-C Target
            • EAS guidance regarding combining Lipid-modifying therapy
          • Statin/ezetimibe SPC for better adherence to LLT
          • Lp(a) as ASCVD risk factor
          • Atherosclerosis: Identifying risks and improving outcomes
          • Act Now for Your ACS Patients: Optimize Your ACS Pathway
          • Act Now for Your ACS Patients: Summary
          • Act Now for Your ACS Patients: Patient Identification
          • Treating to target in clinical practice: Why is it important to achieve recommended LDL-C levels?
          • Act Now for Your ACS Patients: Treat Aggressively, Combine and Start Early
          • Improving Lipid Management for Patients Post-ACS
          • Dyslipidemia performance of 2016 2019 and 2021 ESC Dyslipidemia guidelines
          • The role of the patient in Achieving LDL-C Target
          • Identifying and treating patients with high Lipidaemia risk post-ACS
          • EAS guidance regarding combining Lipid-modifying therapy
          • Lipid management in patients with ACS/ASCVD
        • 2022
          • Lipid-lowering therapy and care gap in patients with Familial Hypercholesterolemia
          • Clinical practice experience in patients with familial hypercholesterolemia (FH) from the Safeheart registry
          • PCSK9 inhibitors and ACS
          • Statin/Ezetimibe Combination VS Statin Monotherapy
          • Single-Pill Combinations in Dyslipidemia
          • Should we encourage earlier and broader use of combination therapies in dyslipidemia?
          • Prescription Trends of Oral Non-Statin LLTs and Their Effects on LDL-C
          • PCSK9i and Prevention of CVD
          • LDL-C The Only Causal Risk Factor for ASCVD
          • CV Risk management in T1DM using guidelines
          • Atherosclerotic Cardiovascular Disease Risk Assessment
          • ACC/AHA vs ESC/EAS LDL–C recommendations for residual risk reduction in ASCVD: A simulation study from Da Vinci
          • Event rates and Risk Factors for Recurrent CV Events
          • PCSK9 Inhibitors in Cardiovascular Disease
          • LDL-C in the management of high cardiovascular risk, changing the paradigm for prevention
          • Public health recommendations for Lp(a) measurement
          • Relationship Between LDL-C LLTs and Risk of Stroke
          • ESC Lp(a) in Clinical practice EAS Consensus statement
          • LLTs Exposure Time and Major Vascular Risk Reduction
        • 2023
          • Lp(a) Levels in Global ASCVD Patients
          • Efficacy of PCSK9i on Lipid Residual Risk Lipid Real Registry
          • 2022 ACC Expert Consensus on ASCVD Management
          • LLT and LDLC Over 2 years in CKD and ASCVD From the Gould Registry
    • Hypertension
    • Thrombosis
  • Chronic Obstructive Pulmonary Disease
    • Cutting Edge Science
      • 2023
        • A deeper look at the inflammation behind exacerbations can IGNITE NEW THINKING IN COPD
      • Innovation
        • A deeper look at the inflammation behind exacerbations in COPD
  • Diabetes
    • Cutting Edge Science
      • 2021
        • Effectiveness of continuous glucose monitoring in adults with Type 2 diabetes treated with basal insulin
        • Unmet needs in adults with T2D receiving premixed insulin
        • Exploring the risk for severe hypoglycemia in the pool of studied patients with T1D
        • The Bright Study
        • New technologies in Type 2 Diabetes management and future opportunities to improve clinical outcomes
        • Insulin Treatment Intensification with GLP - 1RA vs Basal - Plus/Basal - Bolus Regimens
        • Hospitalization Rates for Acute Diabetes Complications Before and After Flash Glucose Monitoring Initiation Among People with Type 1 or Type 2 Diabetes in France: The Relief Study
        • A Cross-Sectional Analysis of Glycemic Control in Elderly People with Type 2 Diabetes Attending Primary Health Care Unit
        • Basal Insulin and Beyond: Advanced Therapies for Type 2 Diabetes
        • Prevalence of Diabetes in Children and Adolescents
        • Reducing risk of severe hypoglycemia - iNPHORM Study
      • Innovation
        • 2022
          • The value of Time-in-range
          • Impact of Time-In-Range on Diabetes Management
          • What Is Time-in-Range?
          • Understanding Time-in-Range: Assessment, Targets, and Benefits for Optimal Glycemic Control
          • Real-world evidence of treatment intensification in people with T2D inadequately controlled on GLP-1 RAs
        • Glargine 300 use in people with type 2 diabetes who fast during Ramadan
        • Advancing Therapy with iGlarLixi: Differentiation from other complex regimens
        • Treatment simplification of complex insulin regimens in T2D
        • Insulin advancement in Type 2 diabetes: Unmet needs with commonly-used options
        • Challenges associated with commonly-used insulin advancement options
        • Advancing Therapy with iGlarLixi: Differentiation from complex insulin regimens
        • EVOLUTION: RWE from Saudi Arabia
        • The InRange Study
        • T1DM Mini-Series: Edition JUNIOR trial results
        • SoliMix Study Results Summary
        • ATTD 2021: Technology Supporting Initiation, Titration, and Intensification
        • Edition Junior Study - Helping patients with type 1 diabetes (T1D) to find better treatment options
        • Time-In-Range (TIR): How to interpret it and how it is associated with outcomes
        • T1DM Mini-Series: The main challenge for the kids and adolescents with T1
        • T1DM Mini-Series: Severe hypoglycaemia compromises the achievement of glycaemic control
        • Do historical HbA1c values explain glycemic legacy effect in type 2 diabetes?
        • T1DM Mini-Series: Clinical implications of having hyperglycaemia with ketosis
        • Diabetes Your Type: Testimonial by Dr. Bassam​
        • T1DM Mini-Series: Relevance of Edition JUNIOR trial results for the HCP and Patient life
        • T1DM Mini-Series: How does Hypoglycaemia impact the life of people with T1 Diabetes?
        • T1DM Mini-Series: How to Avoid Hypoglycaemia in People with T1 Diabetes?
        • The SoliRam observational study
        • Expert consensus statement on management of older adults with type 2 diabetes (T2D)
        • Is Premixed Insulin an Effective Treatment for Type 2 Diabetes Uncontrolled by OADs?
        • Summary of SAGE study on Adults with T1DM
        • ATTD 2021: Patients’ profiles for digital tools
        • The value of Time-in-range
        • Impact of Time-In-Range on Diabetes Management
        • What Is Time-in-Range?
        • Understanding Time-in-Range: Assessment, Targets, and Benefits for Optimal Glycemic Control
        • Real-world evidence of treatment intensification in people with T2D inadequately controlled on GLP-1 RAs
        • ADA 2021: Solimix Trial Summary
        • Diabetes your type: Testimonial by Dr. Nadia
        • Diabetes your type: Testimonial by Dr. Hussein​
      • 2022
        • Patient awareness and attainment of goals in Type 2 Diabetes Mellitus: A real-world survey
        • Diabetes management during Ramadan
        • iGlarLixi Enables Safe Ramadan Fasting for Most T2D Patients
        • Post-exercise hypoglycemia in relation to medication regimen among adults with type 2 diabetes
        • BI hormonal CL systems
        • Recommendations on treatment simplification of complex insulin regimens to improve clinical outcomes in patients with T2DM
        • Enhanced algorithms
        • Improved usability
        • Additional signals
        • Closed-loop insulin delivery during exercise in people with T1D
        • Development of Insulin
        • Case 2 T1D
        • Case 1 T2D
        • A narrative review for clinicians on insulin management for Type 2 Diabetes during Ramadan
        • Benefits of using CGM vs BGM
        • Limitations with the use of BGM
        • Selecting a CGM device
        • Commercially available CGM systems
        • Single injectable treatment may not be enough to get T2DM patient to Glycemic goal
        • Management of athletes and active people with diabetes - The American Medical Society for Sports Medicine (AMSSM) scientific statement
        • Advancing therapy in suboptimally controlled basal insulin-treated type 2 diabetes: Clinical outcomes with iGlarLixi versus premix BIAsp 30 in the SoliMix randomized controlled trial.
        • Single Injectable Treatment May Not Be Enough To Get T2dm Patient To Glycemic Goal
      • 2023
        • New 2022 ADA/EASD Guidelines: GLPP-1 RA/Insulin Combination Is Recommended
      • 2024
        • Groundbreaking SoliD Study: Comparative Efficacy of iGlarLixi and IDegAsp
        • SoliD: Redefine Treatment Paradigm Post-OAD
        • Unveiling Significance of Time in Range: Value as key Glycemic Biomarker
        • Need to redefine the treatment paradigm Post OAD
        • SoliCGM Synergy: Soliqua’s Synchronized Impact on T2DM CGM Dynamics Therapy
        • The Evolving Role of Treatment and Technology in Diabetes Care
        • Time-in-Range: A Key Determinant of Quality of Life
        • The ATOS Study: Real-World Study on Effectiveness of Insulin Glargine U300 in the Gulf Region.
        • An Evidence about The Role of Basal Insulin Glargine 300 U/mL Post-GLP-1 Therapy
        • Connectivity Canvas: Pioneering Diabetes Management with Connected Insulin Caps
        • Inside Diabetes: ATTD Edition | Type 1 Diabetes
  • Eosinophilic Esophagitis
    • Cutting Edge Science
      • 2022
        • Measures of disease severity in eosinophilic esophagitis (EoE)
        • Measures of disease severity in eosinophilic esophagitis (EoE)
        • Measures of disease severity in eosinophilic esophagitis (EoE)
        • Understanding eosinophilic esophagitis (EoE)
      • 2024
        • EOE Pediatric - Unmasking the Hidden Symptoms
        • Importance of assessing key disease domains in EOE
      • Innovation
  • Multiple Myeloma
    • Cutting Edge Science
      • 2022
        • Patients Factors & Impacts
        • Myeloma Facts
        • About MRD
        • Minimal Residual Disease
        • MRD FAQs
        • Importance of MRD
        • Experts Perspective
        • True Cost of Multiple Myeloma
        • The Future of MRD
      • 2023
        • Multiple Myeloma: Elderly Patients
        • Multiple Myeloma: High Risk Cytogenetics
        • Multiple Myeloma: Renal Impairment
        • Lenalidomide Refractory Patients
        • Multiple Myeloma: Minimal Residual Disease
        • Multiple Myeloma: Chromosome 1q+ cytogenetic abnormalities
  • Multiple Sclerosis
    • Cutting Edge Science
      • 2022
        • The reason for MS – beyond focal inflammation
        • The importance of deep grey matter in MS
        • Measuring brain atrophy. What can be done and where are we heading?
        • Falling chronically ill – How do I cope and move forward?
        • Cognitive decline – The invisible burden of MS?
        • Cognitive training – A curse or a blessing?
        • How old is your brain?
        • Exercise as ”medicine” in the treatment of MS
        • A promising biomarker in MS: Neurofilament light chain
        • Why has our brain suddenly become of interest?
        • Thalamic atrophy as a new biomarker of MS? The predictive value and how to use in clinical practice
        • MS Updates
      • Innovation
        • 2021
          • Teri-Pro Study
        • 2022
          • Slowing of brain atrophy with Teriflunomide
      • 2023
      • 2024
        • Learning aRMMs
  • Nasal Polyps
    • Cutting Edge Science
      • 2021
        • About Type 2 Inflammation – Nasal Polyps
      • 2022
        • Look beyond the symptoms to identify and manage Patients with Type 2 Inflammation
        • N-Pass Handbook
      • 2023
        • Hear From An Expert On Identify Patients Who Are Appropriate Candidates For Biologic Treatment
        • When DUPIXENT is available, I would say go for it
        • What can biologic treatment do for patients with CRS with nasal polyps?
        • Rethink Your Nasal Polyps. Type 2 Inflammation A Nasal Polyp Mystery
        • Pneumology Meets Oto-Rhino-Laryngology: A Discussion of Type 2 Inflammation in Airway Diseases
        • Hear From An Expert On Would You Consider A Biologic For A Surgery-Naïve Patient With Crs With Nasal Polyps?
        • Type 2 Inflammation Is The Underlying Cause Of Crswnp In 80% Of Patients.
        • Hear From An Expert On What Have You Learned From Your Experience With Biologics?
        • Hear From An Expert On What Does The Future Of Treatment Look Like For Crs With Nasal Polyps?
        • Hear From An Expert On What Does Dupixent Bring To Your Practice?
        • Hear From An Expert On What Are The Main Challenges In Treating Patients With Crs With Nasal Polyps?
        • Hear From An Expert On The Type 2 Immune Response And Inflammation
        • Hear From An Expert On Identifying Patients Who Are Appropriate Candidates For Biologic Treatment
        • Hear From An Expert On How Does Dupixent Target Underlying Type 2 Inflammation?
        • Hear From An Expert On How Do You Manage Treatment Compliance Issues In Patients With Crs With Nasal Polyps?
        • Hear From An Expert On How Do You Address Patients' Concerns About Sinus Surgery?
        • Hear From An Expert On How Can You Limit The Effects Of Systemic Steroid Use For Patients With Crs With Nasal Polyps?
        • Expert Opinions: Would You Consider A Biologic For A CRSwnp Patient Who Has Had Sinus Surgery?
        • NPS improvement with Dupixent over time
        • IL4/IL13 are the central cytokines for type 2 inflammation in CRSwNP
        • You can imagine more than 90% of CRSwNP patients losses their ability's of smell
        • Compelling trial results: CRS with nasal polyps
        • What does patient empowerment mean for your treatment plan?
        • “Smell—we call it the Cinderella of the senses"
        • "It really has changed the way I manage our patients"
        • How do you factor safety into treating patients with CRSwNP?
        • How does Dupixent help recover smell?
      • 2024
        • Daily Burden of CRSwNP
  • Neurological Disorders
    • Cutting Edge Science
      • 2023
        • Epilepsy Do’s and Don’ts
  • Prurigo Nodularis
    • Cutting Edge Science
      • 2022
        • There is significant unmet need in the management of PN¹
        • Mechanism of Prurigo Nodularis Disease
        • Prurigo Nodularis is a distinct, Chronic, Neural and Immune- Mediated skin disease characterized by intense itch and Nodular Lesions¹
        • Type 2 Inflammation may play a role in Prurigo Nodularis Pathophysiology1
  • Rare Diseases
    • Cutting Edge Science
      • Innovation
        • 2022
          • Respiratory Impairment in Acid Sphingomyelinase Deficiency (ASMD): A Case Report.
          • Inspiring Stories of Patients Living with ASMD
          • The Role of Pediatrician in Gaucher Disease
          • ASMD Phenotypes
        • Better care for Fabry
        • How To Diagnose LSDs?
        • Gaucher disease awareness month video
        • Diagnostic Algorithm for Gaucher Disease in Adult
        • Bone Monitoring Guidelines in Gaucher Disease Video
        • Diagnostic Algorithm for Gaucher Disease in Pediatric
        • Have you considered Pompe Disease?
        • Social stigma
        • The role and importance of Patients Associations and Scientific societies ; UAE experience
        • IOPD Challenges
        • Multidisciplinary approaches in Rare Disease Patient management in KSA
        • What are the new diagnostics modalities used to expedite Rare Disease patients identification?
        • Fabry Disease from Cardiology Perspective
        • When shall we think of a rare disease from Neurological perspective
        • What are Lysosomal Storage disorders?
        • Lysosomal Storage Diseases from Neurology Perspective
        • Extraordinary measures: what are the benefits to have such movies talking about Rare Diseases?
        • The Stigma of Rare Diseases
        • The role and importance of Patients Associations and Scientific societies ; Oman Experience
        • Multidisciplinary approaches in Rare Disease Patient management
        • How is LSDs prevalence & epidemiology different in our region?
        • What is the role of Artificial Intelligence in accelerating patient's diagnosis?
        • LSDs overview
        • Respiratory Impairment in Acid Sphingomyelinase Deficiency (ASMD): A Case Report.
        • Professor Fatma Al-Jasmi video on ASMD
        • Professor Tawfeq Ben Omran video on ASMD
        • Professor Moeen Al Sayed video on ASMD
        • Pompe video
        • Diagnostic challenges of LOPD
        • Early diagnosis and management of IOPD
        • Inspiring Stories of Patients Living with ASMD
        • Their Stories shaped them like Pearls
        • The Role of Pediatrician in Gaucher Disease
        • ASMD Phenotypes
      • 2022
        • How do you know if you or a loved one has ASMD?
        • How is ASMD inherited?
        • What is ASMD?
        • MPSI – Endocrinology Case Study
        • MPSI – Rheumatology Case Study
        • MPSI – ENT Case Study
      • 2023
        • Gaucher
        • Differential Diagnosis Of Late Onset Pompe Disease (LOPD) and Myotonic Dystrophy Type 1 Through Abdominal Ultrasonography
        • Prevalence Of LOPD In Patients With Undifferentiated Proximal Myopathy And Undiagnosed Muscle Biopsy
        • Expert Group Consensus From The Arabian Peninsula On The Diagnosis Of Late Onset Pompe Disease for orthopedists
        • Experts recommendations on Late Onset Pompe Disease (LOPD) differential diagnosis from GCC
        • Expert Group Consensus From The Arabian Peninsula On The Diagnosis Of Late Onset Pompe Disease (LOPD)
        • Expert Group Consensus From the Arabian Peninsula On the Diagnosis of Lopd
        • Expert Group Consensus From the Arabian Peninsula On the Diagnosis of Lopd
        • An overview of Lysosomal Storage Disorders & Sanofi`s Commitment to the Development and Provision of Treatments
        • Fabry
        • Pompe
      • 2024
        • Uncover ASMD and GAUCHER
        • Legacy Video for Rare Disease Academy
        • ASMD
        • What Are the Signs and Symptoms of ASMD?
        • Navigating the Pompe Disease Journey
        • Pompe Care Podcast Series
        • Consensus Guidelines for the Clinical Management of ASMD
        • Impact of symptoms and risk of ASMD on patients and caregivers
        • Differential diagnostics for ASMD in patients suspected to have GD
        • ROLE OF ECG IN DIFFERENTIAL DIAGNOSIS OF ANDERSON–FABRY DISEASE WITH HCM
        • BIOCHEMICAL DIAGNOSTIC STRATEGY IN FEMALES SUSPECTED OF FABRY DISEASE
        • DIAGNOSING FABRY DISEASE IN CLINICAL PRACTICE
  • Vaccines
    • Influenza
      • Cutting Edge Science
        • innovation
          • Sanofi Pasteur at Glance
          • Sanofi Pasteur at Glance
          • Sanofi Pasteur at Glance
        • 2022
          • Take a Stand Against Influenza: Focus on Cardiovascular Disease Patients
        • 2023
          • Flu and Vaccination
          • Flu and Diabetes
          • Flu and Respiratory Disease
          • Flu and Cardiovascular Disease
    • Meningitis
      • Cutting Edge Science
        • Innovation
          • 2022
        • 2022
        • 2024
    • Pertussis Polio
      • Cutting Edge Science
        • 2022
    • RSV
      • Cutting Edge Science
        • 2023
          • RSV History
          • Burden of Disease
          • Rattle
          • RSV
          • All Infant Protection
        • 2024
          • Beyfortus®, an innovative immunization
          • Implementing Beyfortus successfully
          • Beyfortus in Action ECMMID
          • 2024 RSV International Congress ECMMID
          • Implementing Beyfortus successfully (ES)
          • Implementing Beyfortus successfully (FR)
          • Beyfortus in Action
          • Implementing Beyfortus successfully (US)
          • 2024 RSV International Congress - ESPID
          • Nirsevimab : Clinical Experience
          • Real World Evidence Impact of universal immunization with Nirsevimab
• Legal Notice
• Cookie Policy
• Privacy Policy
• Search
• My Account
  • Personal Information
  • Preferences
  • Subscriptions
  • Change Password
  • Unsubscribe
• Incomplete Profile Notice
• Incomplete Profile
• Patient Support
  • Patient Support Articles
  • Atopic Dermatitis
    • 2022
      • EASI Calculator
      • ADCT – Atopic Dermatitis Control Tool
      • Scoring Atopic Dermatitis (SCORAD) Calculator (0.9.0)
    • 2021
  • Cardiovascular
    • 2022
      • Cardio-Risk app
      • Act Now for your ACS Patients
  • Diabetes
    • 2022
      • Insulin and Other Medications Dose Adjustments for Type 1 and 2 Diabetes in Ramadan
    • 2021
    • 2023
    • Tools And Resources
      • Pre-Ramadan assessment and Risk calculation for people with diabetes who want to fast during Ramadan
      • Clinical and economic value of Soliqua - Pharmacist perspective
  • Nasal Polyps
    • 2022
      • N-Pass Tool
      • N-Pass Tool
        
      • N-PASS Follow Up Form
  • Rare Diseases
    • 2021
      • How to diagnose Pompe Disease
      • How To Diagnose Gaucher Disease
      • How to diagnose Fabry disease
    • 2022
• Error 404
• Qatar Contact Details
• Events Calendar
  • Dia-Tour Webinar: Smart Choices for Intensification
• Products
  • Adacel®
  • Aubagio®
    • Aubagio vs Ofatumumab
  • Cablivi®
    • HERCULES Study
      • Study Design
      • Hercules Summary
      • Platelet Count Normalization
      • aTTP-Related Events
      • Recurrences
      • Healthcare Resource Utilization
      • CABLIVI Safety Profile
    • aTTP Diagnosis and Treatment
      • Mechanism of Disease
      • CABLIVI Mechanism of Action
      • ISTH TTP Guidelines
    • Early Treatment Initiation
      • Real-World Evidence Studies
        • CNR-MAT Registry Study
        • Spanish
        • REACT-2020 and Aggregated Analysis
        • Italian
      • ISTH TTP Guidelines
      • CABLIVI-Specific Treatment Recommendation
      • Post-HERCULES
    • Delay in CABLIVI Start
      • Patient Outcomes
      • Active Disease
    • aTTP Sphere Digital Case Library
      • aTTP Sphere Digital Case Library - Kuwait
      • aTTP Sphere Digital Case Library - Qatar
      • TTP Patient Case Study in UAE
      • TTP Patient Case Study in KSA
      • TTP Patient Case Study in UAE
  • Cerezyme®
  • Clexane®
    • Surgical Patients
    • Hemodialysis
  • Dupixent®
    • Prurigo Nodularis
    • Atopic Dermatitis
    • Dupixent® COPD
  • Fabrazyme®
    • Quantifying the Effect of Fabrazyme
    • Canadian Fabry Disease Initiative
    • Long Term Renal Function
  • Lemtrada®
  • Myozyme®
  • Nexviazyme
    • Nexviazyme Dosing and Administration Video
  • Plavix®
    • Tolerability
  • Praluent®
    • Praluent 300 mg
  • Renvela®
  • Sarclisa®
    • Sarclisa®
    • Sarclisa KD®
    • Sarclisa PD®
  • Solian®
  • Soliqua®
    • For a Peaceful Ramadan
    • Soli-Simplify Study
    • Soliqua SoliD®
    • Soliqua Easy Start®
    • Soliqua Guidelines®
    • Soliqua Data Set®
    • Soliqua Simplicity®
    • Soliqua Safety®
    • Soliqua®
  • Tavanic®
  • Toujeo®
    • Toujeo for a Peaceful Ramadan
    • Wall of Evidence
    • Toujeo T1DM
      • OneCare
      • Edition Junior
      • UltraFlexi-1
      • Type-1 Meta Analysis
      • Guidelines
    • Toujeo T2DM
      • Deliver-G
      • Guidelines
    • How to Start
    • Toujeo Innovation
      • Toujeo Upgrade to Win
    • Time in Range
  • Xatral®
  • Xenpozyme®
  • Zympass®
    • Tolerability
    • Usage
• Events
  • Events
  • Anti Infectives
    • 2022
      • Roadmap to antimicrobial prescribing
    • 2023
      • Action and Resistance Mechanisms of Antibiotics
  • Cardiovascular
    • 2022
      • Challenges of VTE Prophylaxis in Surgery
      • Venous Thromboembolism in Acutely Medically Ill Patients
      • Venous Thromboembolism Burden
      • Dyslipidemia Webisodes: Mortality data with Prof. Tunon
    • 2023
      • CardioRisk WebApp
      • World Hypertension Day Ep. 2
      • World Hypertension Day Ep. 1
    • 2021
      • VTE Safety Zone: Assessing the VTE Risk in Hospital and Beyond
      • VTE Safety Zone: Prof. Juan Arcelus - Primary VTE Prophylaxis in Patients with Cancer Undergoing Major Abdominal/Pelvic Surgery
      • Dyslipidemia Expert Exchange: Best practice approaches in dyslipidemia management
      • VTE Safety Zone: VTE in general surgery from risk assessment to appropriate thromboprophylaxis
      • VTE Safety Zone: Primary VTE Prophylaxis in Patients with Cancer Undergoing Major Abdominal/Pelvic Surgery
      • VTE Safety Zone: The Role of Thromboprophylaxis for the Prevention of VTE
      • Dyslipidemia Webinars: Optimizing Dyslipidemia management​
  • Diabetes
    • 2021
      • Insulin@100 Live Webinar​. Discovery. Transformation. Legacy.
      • Soliqua and Unmet Needs Webinar Summary
    • 2022
      • Diatour Inquiry Form
      • Innovation of Iglarlexi in Intensification
      • Innovation of Iglarlexi in Intensification
      • Ultimate Need for Intensification
      • The Role of Basal Insulin in Type 2 Diabetes Webinar
      • Leveraging Time-In-Range to Improve Patient Experience
      • Navigate new destinations in diabetes management
      • Type 2 Diabetes Cost Effective Management
      • Diabetes Guidelines in Ramadan
      • Nutrition and Insulin management in Ramadan
    • 2023
      • Safe & Smart - Dr. Salah
      • World Diabetes Day
      • Safe & Smart - Dr. Kalra
      • Safe & Smart - Dr. Nabil
      • Safe & Smart - Dr. Khudhair
      • Safe & Smart: Cardio Safe & Gluco Smart Approach in Diabetes Management
      • Amaryl Safe & Smart: Cardio Safe & Gluco Smart Approach in Diabetes Management
      • GAED 2023
      • Cardiometabolic Approach in Diabetes Management
      • Treating Type 2 Diabetes Today - How is it Changing?
    • 2024
      • Dia-Tour: Navigating New Destinations in Diabetes Management
• Sitemap
• Registration